Korean J Urol.  2013 Mar;54(3):177-182.

Bone and Metabolic Markers in Women With Recurrent Calcium Stones

• Arrabal-Polo MA
• Arrabal-Martin M
• Arias-Santiago S

Abstract

PURPOSE
The target of our work was to study several biochemical parameters in phospho-calcic and bone metabolism in blood and urine and the bone mineral density of women with recurrent calcium nephrolithiasis.
MATERIALS AND METHODS
We conducted a cross-sectional study with a control group of 85 women divided into 3 groups: group 1 consisted of 25 women without a history of nephrolithiasis, group 2 consisted of 35 women with only one episode of calcium nephrolithiasis, and group 3 consisted of 25 women with a history of recurrent calcium nephrolithiasis. Blood and urine biochemical study was performed, including markers related to lithiasis, and a bone mineral density study was done by use of bone densitometry.
RESULTS
Patients in group 3 showed statistically significantly elevated calciuria (15.4 mg/dL), fasting calcium/creatinine ratio (0.14), and 24-hour calcium/creatinine ratio (0.21) compared with groups 1 and 2. Moreover, this group of women with recurrent calcium nephrolithiasis had significantly elevated values of beta-crosslaps, a bone resorption marker, compared with groups 1 and 2 (p=0.000) and showed more bone mineral density loss than did these groups.
CONCLUSIONS
Recurrent calcium nephrolithiasis in women has a significant association with bone mineral density loss and with values of calciuria, both fasting and 24-hour.

Keyword

Bone density; Calcium; Urolithiasis; Women

MeSH Terms

Bone Density
Bone Resorption
Calcium
Cross-Sectional Studies
Fasting
Female
Humans
Lithiasis
Nephrolithiasis
Urolithiasis
Calcium

Reference

1. Lancina Martin JA, Rodriguez-Rivera Garcia J, Novas Castro S, Rodriguez Gomez I, Fernandez Rosado E, Alvarez Castelo L, et al. Metabolic risk factors in calcium urolithiasis according to gender and age of the patients. Actas Urol Esp. 2002. 26:111–120.

2. Yagisawa T, Hayashi T, Yoshida A, Kobayashi C, Okuda H, Ishikawa N, et al. Comparison of metabolic risk factors in patients with recurrent urolithiasis stratified according to age and gender. Eur Urol. 2000. 38:297–301.

3. Konstantinova OV, Ianenko EK, Dzeranov NK. Recurrence-free and recurrent urolithiasis: metabolic differences. Urologiia. 1999. (5):8–9.

4. Menditto VG, Milanese G, Muzzonigro G. Metaphylaxis of urolithiasis. Arch Ital Urol Androl. 2009. 81:32–39.

5. Caudarella R, Vescini F, Buffa A, La Manna G, Stefoni S. Osteoporosis and urolithiasis. Urol Int. 2004. 72:Suppl 1. 17–19.

6. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008. 42:467–475.

7. Arrabal-Polo MA, Arrabal-Martin M, de Haro-Munoz T, Poyatos-Andujar A, Palæo-Yago F, Zuluaga-Gomez A. Biochemical determinants of severe lithogenic activity in patients with idiopathic calcium nephrolithiasis. Urology. 2012. 79:48–54.

8. Amaro CR, Goldberg J, Amaro JL, Padovani CR. Metabolic assessment in patients with urinary lithiasis. Int Braz J Urol. 2005. 31:29–33.

9. Marangella M, Vitale C, Bagnis C, Bruno M, Ramello A. Idiopathic calcium nephrolithiasis. Nephron. 1999. 81:Suppl 1. 38–44.

10. Areses Trapote R, Urbieta Garagorri MA, Ubetagoyena Arrieta M, Mingo Monge T, Arruebarrena Lizarraga D. Evaluation of renal stone disease: metabolic study. An Pediatr (Barc). 2004. 61:418–427.

11. Spivacow FR, del Valle EE, Zancheta JR. Renal lithiasis. Biochemical changes in the follow-up. Medicina (B Aires). 2006. 66:201–205.

12. Vella M, Karydi M, Coraci G, Oriti R, Melloni D. Pathophysiology and clinical aspects of urinary lithiasis. Urol Int. 2007. 79:Suppl 1. 26–31.

13. Caudarella R, Vescini F, Buffa A, Sinicropi G, Rizzoli E, La Manna G, et al. Bone mass loss in calcium stone disease: focus on hypercalciuria and metabolic factors. J Nephrol. 2003. 16:260–266.

14. Tsuji H, Umekawa T, Kurita T, Uemura H, Iguchi M, Kin K, et al. Analysis of bone mineral density in urolithiasis patients. Int J Urol. 2005. 12:335–339.

15. Giannini S, Nobile M, Dalle Carbonare L, Lodetti MG, Sella S, Vittadello G, et al. Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis. Eur J Endocrinol. 2003. 149:209–213.

16. Enrique CT. Osteoporosis: consideraciones diagnosticas y terapéuticas. Rev Med Hered. 2004. 15:101–107.

17. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006. 119:4 Suppl 1. S25–S31.

18. Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, et al. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J. 2005. 52:667–674.

19. Tiselius HG. Advisory Board of European Urolithiasis Research and EAU Health Care Office Working Party for Lithiasis. Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease. BJU Int. 2001. 88:158–168.

20. Arrabal-Martin M, Fernandez-Rodriguez A, Arrabal-Polo MA, Garcia-Ruiz MJ, Zuluaga-Gomez A. Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides. Urology. 2006. 68:956–959.

21. Legroux-Gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B. Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine. 2004. 71:51–55.

22. Arrabal Martin M, Diaz de la Guardia FV, Jimenez Pacheco A, Lopez Leon V, Arrabal Polo MA, Zuluaga Gomez A. The treatment of renal lithiasis with biphosphonates. Arch Esp Urol. 2007. 60:745–754.

23. Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, et al. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant. 2009. 24:1472–1477.